Semaglutide and Tirzepatide
Records checked
Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk
Qualified clinical review None on record
Semaglutide and Tirzepatide are curated as a pair under Incretin receptor agonists. This page reads them across four axes at once: what each one is recorded as binding, what the molecule is, what shape its indexed record set has, and what the application register returned. Every cell is either a sourced value or a count of records.
A larger record count is not a better compound. Counts track how long a compound has been studied and how heavily it has been indexed, nothing else. Nothing on this page ranks the two.
Identity and target
| Axis | Semaglutide | Tirzepatide |
|---|---|---|
| Class as recorded | Incretin receptor agonists | Incretin receptor agonists |
| Receptor targets as recorded | GLP-1 receptor | GIP receptor, GLP-1 receptor |
| Molecular formula | C187H291N45O59[4] | C225H348N48O68[12] |
| Molecular weight | 4114 g/mol[4] | 4813 g/mol[12] |
| CAS registry number | 910463-68-2[4] | 2023788-19-2[12] |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
| Applications on the register | 1 on the query date[5] | 2 on the query date[13] |
Shape of the indexed record set
| Axis | Semaglutide | Tirzepatide |
|---|---|---|
| Records indexed here | 12 | 12 |
| Phase 3 records | 3 | 7 |
| Phase 2 records | 1 | 1 |
| Phase 1 records | 0 | 0 |
| Trial records with no phase assigned | 3 | 3 |
| Review or synthesis records | 0 | 0 |
| Records that are not registered trials | 5 | 1 |
| Study models as assigned | human trial 10; other 2 | human trial 10; other 2 |
| Publication years covered | 2024–2025 | 2024–2025 |
| Derived record-set tier | Human trial evidence | Human trial evidence |
| Basis of that tier | 10 of 12 indexed records are interventional human trials by their own assigned publication type | 10 of 12 indexed records are interventional human trials by their own assigned publication type |
| Review state | Pending qualified review | Pending qualified review |
The derived tier counts record types. It is not an assessment of clinical efficacy, of safety, of study quality or of consensus, and the two tiers on this row are not a verdict about which compound is better supported.
Endpoint coverage, side by side
| Axis | Semaglutide | Tirzepatide |
|---|---|---|
| Body weight and adiposity | 7 | 9 |
| Glycaemic control | 5 | 3 |
| Cardiovascular | 6 | 6 |
| Renal | 2 | 0 |
| Hepatic | 1 | 1 |
| Neurological | 0 | 0 |
Each endpoint is defined by a fixed set of subject headings, printed in full on the endpoint pages.
Which axes diverge
10 of the 23 axes above differ between the two, 12 carry the same value, and 1 are unsourced on both sides. A divergence is a difference in what the corpus records, not a difference in what either compound does.
| Result | Axes |
|---|---|
| Differ | Receptor targets; Molecular formula; Molecular weight; CAS registry number; Applications on the register; Phase 3 records; Non-trial records; Body weight and adiposity records; Glycaemic control records; Renal records |
| Same value | Class as recorded; Records indexed; Phase 2 records; Phase 1 records; Unphased trial records; Review records; Study models; Publication years; Derived record-set tier; Cardiovascular records; Hepatic records; Neurological records |
| Unsourced on both sides | Reported half-life |
The corpus also carries a curated divergence note for this pair, written for the reference layer rather than for this one. It is not reproduced here; the records behind it are cited[1, 2, 3] and listed in the sources below.
Records indexed under both
2 records are indexed under both compounds. That is the only direct head-to-head signal this corpus holds, and it says the record exists, not what it reported.
Phase 3 — 1 record
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 1 | pmid:40353578 | 2025 | Tirzepatide as Compared with Semaglutide for the Treatment of Obesity The New England journal of medicine · Clinical Trial, Phase III, Comparative Study | human trial | Humans; Obesity; Body Weight; Weight Loss; Anti-Obesity Agents; Treatment Outcome; Injections, Subcutaneous; Maximum Tolerated Dose |
Not a registered trial record — 1 record
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 2 | pmid:38976257 | 2024 | Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity JAMA internal medicine · Comparative Study, Research Support, Non-U.S. Gov't | other | Humans; Obesity; Weight Loss; Anti-Obesity Agents; Retrospective Studies; Cohort Studies; Adult; Aged |
Where this page sits
- Semaglutide: the full indexed record set
- Tirzepatide: the full indexed record set
- Every curated pair in this class
Sources
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med (2021). pmid:34170647
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (2021). pmid:34186022
- Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther (2024). pmid:39289339
- PubChem Compound Summary for CID 56843331, Semaglutide. PubChem, National Library of Medicine (2026). pubchem:56843331
- Drugs@FDA application register query for this compound, 1 application(s) returned: NDA213051. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:semaglutide
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med (2016). pmid:27633186
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med (2021). pmid:33567185
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med (2023). pmid:37952131
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med (2021). pmid:33185364
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med (2024). pmid:38785209
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ (2024). pmid:38286487
- PubChem Compound Summary for CID 166567236, tirzepatide. PubChem, National Library of Medicine (2026). pubchem:166567236
- Drugs@FDA application register query for this compound, 2 application(s) returned: NDA215866, NDA217806. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:tirzepatide
- Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med (2022). pmid:35658024
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med (2024). pmid:38856224
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med (2025). pmid:39555826